Q2 2023 13F Holders as of 30 Jun 2023
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
61,827,467
-
Number of holders
-
67
-
Total 13F shares, excl. options
-
39,734,743
-
Shares change
-
-34,289
-
Total reported value, excl. options
-
$272,184,520
-
Value change
-
-$3,199,539
-
Number of buys
-
41
-
Number of sells
-
-20
-
Price
-
$6.85
Significant Holders of Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE) as of Q2 2023
79 filings reported holding GLUE - Monte Rosa Therapeutics, Inc. - COMMON STOCK as of Q2 2023.
Monte Rosa Therapeutics, Inc. - COMMON STOCK (GLUE) has 67 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 39,734,743 shares
of 61,827,467 outstanding shares and own 64% of the company stock.
Largest 10 shareholders include NEA Management Company, LLC (7,692,298 shares), FMR LLC (6,545,732 shares), Avoro Capital Advisors LLC (4,535,000 shares), PRICE T ROWE ASSOCIATES INC /MD/ (3,896,498 shares), BlackRock Inc. (3,860,356 shares), BAKER BROS. ADVISORS LP (3,023,951 shares), VANGUARD GROUP INC (1,556,788 shares), Aisling Capital Management LP (1,472,331 shares), Alphabet Inc. (1,464,015 shares), and CITADEL ADVISORS LLC (771,764 shares).
This table shows the top 67 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.